EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


LinkedIn facebook twitter youtube
News archive

 

MPE will hold a focus group to find out more about CAR-T from a patient perspective. We will be asking questions that relate to quality of life measurement within CAR-T clinical trials and to the wider impact of CAR-T on individuals and their partners, family members, carers, or friends.

 

The focus group discussions will last for 75 minutes each. You will be compensated for your time at a rate of €62.50 / hour, plus any time that you need to prepare or debrief.

 

For more details, click on the link to read more about it in the language you prefer:







Recent news

» Job offer – Head of Patient Research

» The European Medicines Agency (EMA) approves Melflufen (Pepaxti®) for the treatment of refractory myeloma

Leave a Reply

Your email address will not be published.

I accept the Privacy Policy